[SCHEDULE 13G/A] Okta, Inc. SEC Filing

Rhea-AI Filing Summary

FMR LLC, together with Chair & CEO Abigail P. Johnson, submitted Amendment No. 7 to Schedule 13G for Regeneron Pharmaceuticals (REGN). The group reports beneficial ownership of 3,359,562.56 common shares, representing 3.2 % of the class as of 30 Jun 2025, and therefore affirms “ownership of 5 percent or less.”

FMR discloses sole voting power over 3,156,857.64 shares and sole dispositive power over the full 3,359,562.56 shares; no shared voting or dispositive authority exists. The position is held in the ordinary course of business under Rule 13d-1(b) and is not intended to influence control of the issuer. Signatures were executed by attorney-in-fact Richard Bourgelas on 5 Aug 2025.

Key takeaway: Fidelity-affiliated entities remain a significant institutional holder, yet their stake has slipped below the 5 % threshold that would otherwise trigger a Schedule 13D filing.

Positive

• None.

Negative

• FMR LLC’s ownership fell to 3.2 %, dropping below the 5 % threshold, indicating a reduction of institutional support or possible share sales.

Insights

Financial Analyst

TL;DR – Fidelity now owns 3.2 % of REGN, down from >5 %, signaling modest divestment but still a sizeable long-term stake.

The filing confirms that FMR LLC and Abigail P. Johnson collectively control 3.36 m REGN shares. Moving below the 5 % mark eliminates additional reporting burdens and can indicate either measured selling or issuer share count changes. With sole voting and dispositive authority, Fidelity remains an influential top-tier shareholder, yet the reduced stake may lessen any perception of an activist role. Because REGN’s float exceeds 100 m shares, a 3 % position is material but unlikely, on its own, to move the stock. Overall impact: modestly negative sentiment due to reduced institutional ownership but fundamentally neutral for long-term outlook.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

OKTA INC

(Name of Issuer)

CLASS A COMMON STOCK

(Title of Class of Securities)

679295105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 679295105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,028,232.71
6	Shared Voting Power 0.00
7	Sole Dispositive Power 16,220,815.96
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,220,815.96

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 679295105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 16,220,815.96
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,220,815.96

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OKTA INC
(b)	Address of issuer's principal executive offices: 100 FIRST STREET,SUITE 600,SAN FRANCISCO,CA,US,94105
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: CLASS A COMMON STOCK
(e)	CUSIP No.: 679295105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 16220815.96
(b)	Percent of class: 9.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 16220815.96
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of OKTA INC. No one other person's interest in the CLASS A COMMON STOCK of OKTA INC is more than five percent of the total outstanding CLASS A COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How much of Regeneron (REGN) does FMR LLC currently own?

The filing lists 3,359,562.56 shares, equal to 3.2 % of outstanding common stock.

Did Fidelity’s stake fall below 5 % in this amendment?

Yes. Item 5 confirms ownership of 5 percent or less, with the exact stake at 3.2 %.

What voting power does FMR report over REGN shares?

FMR has sole voting power over 3,156,857.64 shares and no shared voting power.

Is this a passive or activist filing?

Filed under Rule 13d-1(b) as a passive institutional investor; the group states no intent to influence control.

Who signed the Schedule 13G/A on behalf of FMR LLC?

Attorney-in-fact Richard Bourgelas signed on 5 Aug 2025 under a power of attorney dated 23 May 2023.